Diazyme: finalize design verification, obtain regulatory approval (EUA and 510K), scale up production and deploy the diazyme sars-COV-2 neutralizing antibody clia kit.
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50122C00015
- Awardee
-
Diazyme Laboratories Inc. UEI CMPJCEGG54S7
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $3,202,772
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · BAA18100SOL00003 · Posted Oct 16, 2017
- Contract value 100% obligated
- $3,202,772.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Poway, CA 92064, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$600,000 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,802,772 |
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Diazyme Laboratories Inc. for design verification, regulatory approval, production scale-up, and deployment of a SARS-CoV-2 neutralizing antibody CLIA kit on August 1, 2022, with a ceiling value of $3.2 million under cost-plus-fixed-fee pricing and no set-aside.
The originating Broad Agency Announcement from the Biomedical Advanced Research and Development Authority (BARDA), posted October 16, 2017, sought advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic threats, including diagnostics and production platforms advancing candidates toward FDA approval or licensure. Work is performed in Poway, California.
The contract's ultimate completion date is September 30, 2025. A bilateral modification de-obligated $600,000 from CLIN 0001. In FY2024, the contract invoiced $896 thousand across 2.0 FTEs and 4,149 contractor hours, representing a derived government-paid hourly rate of $215.86/hr. The prime self-performed all reported labor; no subcontractors were reported in FY2024 SCI data.
Subcontractors supporting the effort include Vector Biosource Inc. (bioenzyme and serum/blood services awarded February 21, 2025), Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (technical services, period extended through September 30, 2025 in November 2024), and Colorado State University Sponsored Programs (technical services, period and key personnel revised in September 2024).
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Vector Biosource Inc. | $39,750 | |
| Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | $40,000 | |
| Colorado State University | $82,000 | |
| Subcontractor not on record | $30,000 |
Quick answers
Who was awarded contract 75A50122C00015?
75A50122C00015 was awarded to Diazyme Laboratories Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on August 1, 2022.
How much is contract 75A50122C00015 worth?
The government has obligated $3,202,772 on 75A50122C00015.
Was contract 75A50122C00015 competed?
The extent of competition for 75A50122C00015 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award